



**CONGRESO NACIONAL**  
SOCIEDAD ESPAÑOLA DE ENFERMEDADES  
INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA



**Barcelona**  
26-28 mayo 2016



LO MEJOR DEL AÑO. Sábado, 28 de mayo de 2016

LOS 10 HITOS DEL AÑO EN ENFERMEDADES INFECCIOSAS,  
MICROBIOLOGÍA CLÍNICA Y VIH

**VIH y VHC. Dr. Daniel Podzamczar**

*Unidad VIH y ETS, Servicio de Enfermedades Infecciosas, Hospital  
Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona*

***Citas bibliográficas***



**CONGRESO NACIONAL**  
SOCIEDAD ESPAÑOLA DE ENFERMEDADES  
INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA



**Barcelona**  
26-28 mayo 2016



1. Sterling TR, Scott NA, Miró JM, et al. the Tuberculosis Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26 / ACTG 5259). Three Months of Weekly Rifapentine plus Isoniazid for Treatment of *M. tuberculosis* Infection in HIV Co-infected Persons. *AIDS 2016 (epub ahead of print)*.
2. Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. *N Engl J Med 2016; 374:542-54*.
3. Rhein J, Morawski BM, Huppler Hullsiek K, et al. on behalf of ASTRO-CM Study Team. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. *Lancet Infect Dis 2016 (epub ahead of print)*.



**CONGRESO NACIONAL**  
SOCIEDAD ESPAÑOLA DE ENFERMEDADES  
INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA



**Barcelona**  
26-28 mayo 2016



4. Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med.* 2015; 373 (9): 795-807.
  
5. Sax PE, Wohl D, Yin MT, et al for the GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet* 2015; 385: 2606–15.
  
6. Dinges W, Girard P-M, Podzamczar D, et al. The F4/AS01<sub>B</sub> HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults. A Randomized Controlled Trial. *Medicine* 2016; 95 (6): 1-10.



**CONGRESO NACIONAL**  
SOCIEDAD ESPAÑOLA DE ENFERMEDADES  
INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA



**Barcelona**  
26-28 mayo 2016



7. Molina JM, Capitant C, Spire B, et al. for the ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. *N Engl J Med* 2015; 373:2237-2246.
8. Baeten J, Palanee-Phillips T, Brown ER et al. for the MTN-020–ASPIRE Study Team. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. *N Engl J Med* 2016. (epub ahead of print).
9. Feld JJ, Jacobson IM, Hézode D, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5 and 6 Infection. *N Engl J Med* 2015; 373 (27): 2599-2607.
10. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *Lancet* 2015 Aug;2(8):e319-27